SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

8 Oct 2013 07:00

RNS Number : 9350P
Victrex PLC
08 October 2013
 



 

 

8 October 2013

Victrex plc - Year End Trading Statement

Victrex plc ('Victrex'), an innovative world leader in high performance polymers, today releases its year end trading statement, ahead of its 2013 preliminary results which will be announced on Tuesday 10 December 2013.

Full year sales volume was slightly ahead of last year at 2,920 tonnes (FY 2012: 2,904 tonnes) following a robust second half performance, with sales volume approximately 10% ahead of the first half year. Group sales volume of 1,528 tonnes for the second half was in line with the strong prior year performance (H2 2012: 1,527 tonnes), with good progress across our industrial and transport markets, offset by lower sales in the electronics market following the non-recurrence of last year's strong product launch related sales into consumer electronics.

In our Invibio Biomaterial Solutions business, full year revenue was slightly ahead of the prior year at £50.8m (FY 2012: £50.5m). This reflects steady improvement in sales to the Spine market during the second half year, with revenue 10% ahead of the first half, as inventory levels in the industry appear to have stabilised. Second half revenue in Invibio was also ahead of the prior year at £26.6m (H2 2012: £25.0m). Outside of the Spine market, we continue to see steady progress in our emerging market opportunities.

Outlook

Looking ahead to our new financial year, whilst we remain mindful of the wider economic environment, our order book for October is reassuring. Victrex remains confident in the diverse and multiple growth opportunities that are being developed across the business. Our investment in additional capacity, which is a key enabler to support and deliver our future growth programmes, remains on plan and on budget, with construction progressing well.

Victrex will host an Investor Day, 'Spotlight on Growth', in London this Thursday, 10 October 2013, with its Executive Management Team, including presentations by Tim Cooper, Managing Director of VPS, and Martin Court, Managing Director of Invibio, covering the scale of Victrex's Group wide growth programmes. No new trading or financial information will be disclosed during the Investor Day. 

 

Enquiries:

Victrex plc:

Andrew Hanson, Head of Investor Relations 01253 898121

Steve Barrow, Group Finance Director 01253 897700

 

MHP Communications:

Nick Denton/Barnaby Fry/James White 0203 128 8100

 

Investor and analyst conference call:

A conference call for Investors and Analysts will be held today, Tuesday 8 October, 09.00am. For further details please contact Ben Griffiths at MHP Communications on 0203 128 8100.

 

About Victrex:

Victrex is an innovative world leader in high performance polymers. Every day, millions of people rely on products or applications which contain our materials, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 30 years' experience, we are investing in technology leadership to deliver new solutions to our customers and our markets. Find out more at www.victrexplc.com

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUGGWAUUPWGQM
Date   Source Headline
24th Jun 20249:44 amRNSHolding(s) in Company
14th Jun 20249:00 amRNSAdditional Listing
3rd Jun 20242:19 pmRNSBlock listing Interim Review
3rd Jun 20249:30 amRNSDirector/PDMR Shareholding
31st May 202411:23 amRNSTotal Voting Rights
23rd May 20247:00 amRNSSBTI approval of carbon reduction targets
15th May 20243:59 pmRNSDirector/PDMR Shareholding
14th May 20244:05 pmRNSDirector/PDMR Shareholding
13th May 20247:00 amRNSVictrex plc - Interim Results 2024
7th May 20243:25 pmRNSDirector Declaration
30th Apr 20242:54 pmRNSTotal Voting Rights
28th Mar 20249:56 amRNSTotal Voting Rights
15th Mar 20248:30 amRNSDirectorate Change
6th Mar 20242:06 pmRNSDirector/PDMR Shareholding
29th Feb 20249:36 amRNSTotal Voting Rights
21st Feb 20248:00 amRNSBlock listing Interim Review
9th Feb 202412:16 pmRNSResult of AGM
9th Feb 20247:00 amRNSAGM & Q1 Interim Management Statement
31st Jan 202412:26 pmRNSTotal Voting Rights
25th Jan 202410:57 amRNSHolding(s) in Company
9th Jan 202412:13 pmRNSAnnual Report & Accounts
29th Dec 20239:00 amRNSTotal Voting Rights
12th Dec 202310:21 amRNSDirector/PDMR Shareholding
5th Dec 20232:42 pmRNSDirector/PDMR Shareholding
5th Dec 20232:33 pmRNSDirector/PDMR Shareholding
5th Dec 20237:00 amRNSVictrex plc - Preliminary Results 2023
1st Dec 202310:41 amRNSBlock listing Interim Review
30th Nov 202311:10 amRNSTotal Voting Rights
3rd Nov 20231:31 pmRNSHolding(s) in Company
31st Oct 20239:36 amRNSTotal Voting Rights
19th Sep 20231:59 pmRNSDirector/PDMR Shareholding
8th Sep 20239:32 amRNSHolding(s) in Company
31st Aug 20239:30 amRNSTotal Voting Rights
23rd Aug 202310:52 amRNSHolding(s) in Company
17th Aug 20231:27 pmRNSDirector/PDMR Shareholding
31st Jul 20239:39 amRNSTotal Voting Rights
18th Jul 202311:51 amRNSDirector/PDMR Shareholding
13th Jul 20232:00 pmRNSAdditional Listing
6th Jul 20237:00 amRNSVictrex plc - Q3 Interim Management Statement
3rd Jul 20234:03 pmRNSHolding(s) in Company
30th Jun 20239:37 amRNSTotal Voting Rights
27th Jun 202310:08 amRNSDirector/PDMR Shareholding
19th Jun 20232:27 pmRNSDirector/PDMR Shareholding
14th Jun 20237:00 amRNSTrading Statement
1st Jun 202312:08 pmRNSBlock listing Interim Review
31st May 20239:52 amRNSTotal Voting Rights
17th May 202310:55 amRNSDirector/PDMR Shareholding
16th May 202310:03 amRNSDirector/PDMR Shareholding
12th May 202310:37 amRNSDirector/PDMR Shareholding
11th May 202312:01 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.